## Diana Miao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8020921/publications.pdf

Version: 2024-02-01

23 papers 10,233 citations

361388 20 h-index 25 g-index

26 all docs

26 docs citations

times ranked

26

16766 citing authors

#	Article	IF	CITATIONS
1	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	12.6	2,445
2	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015, 350, 207-211.	12.6	2,275
3	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	12.6	898
4	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature, 2017, 547, 413-418.	27.8	792
5	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231.	8.8	746
6	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine, 2019, 25, 1916-1927.	30.7	541
7	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	21.4	438
8	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity, 2017, 46, 197-204.	14.3	400
9	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	9.4	392
10	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine, 2018, 24, 1143-1150.	30.7	212
11	Intron retention is a source of neoepitopes in cancer. Nature Biotechnology, 2018, 36, 1056-1058.	17.5	212
12	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 4441-4453.	8.2	155
13	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine, 2016, 8, 79.	8.2	151
14	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research, 2017, 5, 84-91.	3.4	126
15	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	28.9	113
16	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications, 2017, 8, 2193.	12.8	99
17	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunology Research, 2016, 4, 820-822.	3.4	63
18	Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discovery, 2020, 10, 1296-1311.	9.4	49

#	Article	IF	CITATIONS
19	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3214-3222.	7.0	44
20	Genomic determinants of cancer immunotherapy. Current Opinion in Immunology, 2016, 41, 32-38.	5.5	27
21	Minimally Invasive Radical Hysterectomy for Cervical Cancer: A Systematic Review and Meta-analysis. Journal of Minimally Invasive Gynecology, 2021, 28, 544-555.e7.	0.6	14
22	The Characteristics of Referring Facilities and Transferred Hand Surgery Patients. Journal of Bone and Joint Surgery - Series A, 2014, 96, e48.	3.0	13
23	Surgical Clinical Trials in Gynecology: Rare, Challenging but Desperately Needed. Journal of Minimally Invasive Gynecology, 2021, 28, 379-383.	0.6	2